Since EGF is a MAPK regulatory target that plays a significant role in breast cancer progression and exhibited the largest changes in our RNA-seq and secretome analyses, we evaluated whether MAPK pathway activation and EGF stimulation were sufficient to induce stem cells to transdifferentiate or replicate from in vivo breast cancer cell transplants. The gene discussed is EGF; the disease is breast cancer.